Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Depreciation and Depletion: 2021-2025

Historic Depreciation and Depletion for InMed Pharmaceuticals (INM) over the last 3 years, with Jun 2025 value amounting to $12,206.

  • InMed Pharmaceuticals' Depreciation and Depletion rose 124.37% to $12,206 in Q2 2025 from the same period last year, while for Jun 2025 it was $50,204, marking a year-over-year increase of 5.16%. This contributed to the annual value of $50,204 for FY2025, which is 5.16% up from last year.
  • As of Q2 2025, InMed Pharmaceuticals' Depreciation and Depletion stood at $12,206, which was up 0.02% from $12,203 recorded in Q1 2025.
  • InMed Pharmaceuticals' Depreciation and Depletion's 5-year high stood at $14,242 during Q4 2023, with a 5-year trough of $4,217 in Q3 2021.
  • In the last 3 years, InMed Pharmaceuticals' Depreciation and Depletion had a median value of $12,562 in 2023 and averaged $12,145.
  • Per our database at Business Quant, InMed Pharmaceuticals' Depreciation and Depletion crashed by 57.88% in 2024 and then spiked by 124.37% in 2025.
  • InMed Pharmaceuticals' Depreciation and Depletion (Quarterly) stood at $6,246 in 2021, then increased by 28.98% to $8,056 in 2022, then skyrocketed by 76.79% to $14,242 in 2023, then decreased by 14.27% to $12,209 in 2024, then spiked by 124.37% to $12,206 in 2025.
  • Its Depreciation and Depletion was $12,206 in Q2 2025, compared to $12,203 in Q1 2025 and $12,209 in Q4 2024.